Peer-reviewed veterinary case report
PET/CT scan predicts survival in dogs with bone cancer
By Griffin, Lynn R et al.·Published in Journal of veterinary internal medicine·2019·Department of Environmental and Radiological Health Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic value of fluorineflourodeoxyglucose positron emission tomography/computed tomography in dogs with appendicular osteosarcoma.
- Species:
- dog
Plain-English summary
A group of 62 dogs with a type of bone cancer called appendicular osteosarcoma were studied to see how a specific imaging test (F-FDG PET/CT) could predict their survival. The results showed that dogs with a higher measurement from the test (known as maximum standard uptake value or SUV) had a shorter median survival time compared to those with a lower SUV. Specifically, dogs with an SUV of 7.4 or higher had a median survival of about 254 days, while those with an SUV below 7.4 lived around 680 days on average. This suggests that the SUV can help veterinarians understand how serious the cancer is and what the likely outcome may be for each dog.
People also search for: dog bone cancer prognosis · appendicular osteosarcoma treatment · F-FDG PET/CT for dogs
Abstract
BACKGROUND: Factors indicative of a negative prognosis for appendicular osteosarcoma (OSA) in dogs are visible metastatic disease, location, and size of lesion. In human medicine maximum standard uptake value (SUV), as measured on a fluorineflourodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT), is prognostic for survival for several tumor types. OBJECTIVE: Determine if SUVis associated with progression-free interval (PFI) and determination of survival in dogs with appendicular OSA. ANIMALS: Sixty-two dogs with untreated appendicular OSA that had been staged withF-FDG PET/CT. METHODS: Retrospective analysis of theF-FDG PET/CT was performed. Dogs were excluded from the study if they did not receive definitive intent treatment for their primary OSA and adjuvant chemotherapy with carboplatin, or had visible metastatic disease on initial imaging. A region of interest (ROI) was created around the primary tumor to measure SUV. Univariable and multivariable Cox proportional hazards analysis was performed to evaluate for associations between variables including SUVand outcome of PFI and overall survival (OS). RESULTS: Maximum standard uptake value of the primary tumor was significantly associated with the OS (P = .04) with adjustment for treatment type and monocyte count. The overall median survival time (OST) was 284 days (range, 39-1293 days) with the OST of dogs having an SUVof ≥7.4 of 254 days (range, 98-428 days) and dogs with an SUVof <7.4 of 680 days (range, 108-811 days, P = .01). CONCLUSIONS AND CLINICAL IMPORTANCE: Maximum standard uptake value as measured viaF-FDG PET/CT is significantly associated with survival in dogs with appendicular OSA with a high SUVbeing an indicator of a negative prognosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30768736/